Clinical trials: Zoledronic acid
Prostate Cancer
Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
The present study will give information about the course over time in skeletal-related events (SRE) in prostate cancer patients with bone metastases treated with zoledronic acid 4 mg administered as a 15-minute infusion every 4…
- Trial name
- NCT00219219
- Testing
- Zoledronic acid
- Where
- Italy
- Sponsor
- Novartis
Prostate Cancer
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
The purpose of this trial with Zometa is to investigate the effect ZOMETA 4 mg (zoledronic acid for injection in 100mg solution ) has in preventing associated bone loss in prostate cancer patients with bone metastasis when…
- Trial name
- NCT00035997
- Testing
- Zometa
- Where
- 56 sites in United States
- Volunteers
- 261 people
- Sponsor
- Novartis Pharmaceuticals
Osteomyelitis Chronic
EFFICACY AND SAFETY OF ZOLEDRONATE VERSUS PLACEBO ON PAIN AT WEEK 12 IN PEDIATRIC PATIENTS WITH CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS
Chronic recurrent multifocal osteomyelitis (CRMO) is a rare auto-inflammatory bone disease that primarily affects children and/or adolescents at a median age of 10 years.
- Trial name
- POMREP (NCT07668583)
- Testing
- Zoledronic Acid / Zoledronate 4 MG/100 ML Intravenous Solution, NaCL 0.9% Intravenous Solution
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer, Bone Metastases
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
The goal of this clinical research study is to find the highest tolerable dose of dasatinib and Zometa (zoledronic acid) that can be given in combination for the treatment of breast cancer that has spread to the bone.
- Trial name
- NCT00566618
- Testing
- Dasatinib, Zoledronic Acid
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma
Evidence for the beneficial effects of bisphosphonates on bone resorption in multiple myeloma has been reported extensively, showing reductions in skeletal events and improvement of several biochemical variables in bone…
- Trial name
- NCT00216151
- Testing
- Zoledronic Acid
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- Hoosier Cancer Research Network
Postmenopausal Osteoporosis
A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years
This study will evaluate the effects of zoledronic acid 5 mg infusion on BMD and biochemical markers of bone in post-menopausal osteoporotic patients aged between 50-65.
- Trial name
- NCT00909961
- Testing
- Zoledronic acid
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Hematopoietic Stem Cell Transplantation
Zoledronic Acid in Combination With Interleukin-2 to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allotransplant
Patients receiving haplo-SCT are at high-risk of relapse. Vγ9Vδ2 T cells exhibit is a well-known population able to exert cytotoxicity toward a large range of tumor in vitro or in vivo.
- Trial name
- HILDEGAZ (NCT03862833)
- Testing
- IL2, Zoledronic Acid
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
Osteoporosis
FES-Rowing Versus Zoledronic Acid to Improve Bone Health in Spinal Cord Injury (SCI)
This is a research study to determine the effects of functional electrical stimulation (FES) rowing and a drug called zoledronic acid in bone health.
- Trial name
- NCT01426555
- Testing
- FES-Rowing, Zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Antonio Lazzari
Breast Cancer
Prospective Breast Cancer Biobanking
Prospective Breast Cancer Biobanking study (PBCB) will apply advanced monitoring in liquid biopsies of early staged breast cancer ration in order to facilitate A.
- Trial name
- PBCB (NCT04488614)
- Testing
- Breast Concervative or Meastectomy
- Where
- 2 sites in Norway
- Volunteers
- 1,200 people
- Sponsor
- Helse Stavanger HF
Osteoporosis
Atorvastatin (Lipitor) to Prevent Bone Pain
In the proposed randomized double blind cross-over placebo controlled study, the researchers intend to investigate if Atorvastatin (FDA approved statin for children) can be used to alleviate the symptom of bone pain (acute phase…
- Trial name
- NCT00120133
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's Mercy Hospital Kansas City
Osteonecrosis
Mononuclear Cells, Platelets and Zoledronic Acid for Preventing Collapse of the Femoral Head in Osteonecrosis
This study was mainly aimed to evaluate the efficacy of local administration of enriched bone marrow mononuclear cells, platelets and zoledronic acid for the clinical prevention of collapse of the early-stage osteonecrotic…
- Trial name
- NCT02721940
- Testing
- Control group, Mononuclear Cells, Platelets
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Controlled Type 2 Diabetic Patients With Periodontitis
Clinical and Radiographic Evaluation of Subgingival 1% Metformin Gel Versus 0.05% Zoledronate Gel as an Adjunct to MINST of Intrabony Defects in Controlled Type 2 DM
The present randomized placebo-controlled trial aims to evaluate and compare the clinical and radiographic efficacy of subgingivally delivered 0.05% zoledronate gel and 1% metformin gel as adjuncts to minimally invasive…
- Trial name
- NCT07753317
- Testing
- All participants will receive MINST
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cairo University
Prostate Cancer
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
The primary objectives of this study are: 1. To explore the antitumor activity of MEDI-522 in combination with docetaxel, prednisone, and zoledronic acid in patients with metastatic Androgen-Independent Prostate Cancer (AIPC)…
- Trial name
- NCT00072930
- Testing
- MEDI-522, Docetaxel + Prednisone* + Zoledronic Acid
- Where
- 57 sites in United States, Belgium and 5 more
- Volunteers
- 150 people
- Sponsor
- MedImmune LLC
Multiple Myeloma, Breast Cancer
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
The primary objective of this study is to investigate the repeat-dose pharmacokinetic (PK) profile of zoledronic acid when administered every 4 weeks versus every 12 weeks, in patients treated with 9-20 infusions of zoledronic…
- Trial name
- NCT00424983
- Testing
- Zoledronic acid
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Postmenopausal
Activity of Pre-Osteoclasts and Osteoclasts Over Time in Postmenopausal Women Treated With Denosumab or Zoledronic Acid
This study evaluates how patients treated with denosumab or zoledronic acid for osteoporosis may change the number of peripheral osteoclast precursors and osteoclast activity, and how that may be associated with changes in bone…
- Trial name
- NCT03812367
- Where
- United States
- Sponsor
- University of California, Davis
Bariatric Surgery Candidate, Bone Loss
Healthy Body, Healthy Bones After Bariatric Surgery Trial
One in three adults in the United States suffers from obesity. Bariatric surgery is an increasingly utilized and effective treatment for obesity and obesity-related comorbidities, however, the massive weight loss associated with…
- Conditions
- Bariatric Surgery Candidate, Bone Loss, Bone Resorption
- Trial name
- NCT04279392
- Testing
- Zoledronic Acid 5 mg/Bag 100 ml Inj
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Charcot Arthropathy, Diabetes Complications
Zoledronic Acid or Methylprednisolone for Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus
Charcot neuropathic osteoarthropathy (CNO) is a progressively destructive process resulting from significant peripheral neuropathy of almost any aetiology. Diabetes mellitus has emerged as the commonest cause of CNO.
- Trial name
- NCT03289338
- Testing
- Zoledronic Acid, Methylprednisolone
- Where
- India
- Volunteers
- 36 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Prostate Cancer
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer.
- Trial name
- STAMPEDE (NCT00268476)
- Testing
- Celecoxib, Docetaxel, Prednisolone
- Where
- 120 sites in Switzerland, United Kingdom
- Volunteers
- 11,992 people
- Sponsor
- Medical Research Council
Neoplasm Metastasis
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
This study will evaluate the safety, tolerability and efficacy of zoledronic acid administered intravenously every 3-4 weeks in patients with bone metastases from either breast cancer or prostate cancer.
- Trial name
- NCT00434317
- Testing
- Zoledronic acid
- Where
- 4 sites in Hungary
- Volunteers
- 80 people
- Sponsor
- Novartis
Leiomyosarcoma
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
Dinutuximab beta was designed to bind to neuroblastoma cells and other cancer cells that express the GD2 antigen, such as STS/LMS cells, and it is believed that this binding "labels" the cells an makes them a better target.
- Trial name
- DiTuSarc (NCT05080790)
- Testing
- Dinutuximab Beta, Zoledronic acid, Interleukin-2
- Where
- 2 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest